Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical pharmacology and therapy

• Publication date

  2010-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.2010.120PMID 20811346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

  2009cited by this paper
• Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan

  2009cited by this paper
• The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.

  2009cited by this paper
• Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers

  2008cited by this paper
• DO MEN AND WOMEN DIFFER IN PROXIMAL SMALL INTESTINAL CYP3A OR P-GLYCOPROTEIN EXPRESSION?

  2005cited by this paper
• Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat

  2004cited by this paper
• Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

  2004cited by this paper
• Sex is a major determinant of CYP3A4 expression in human liver

  2003cited by this paper
• Sex‐related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P‐glycoprotein

  2002cited by this paper
• Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A.

  2000cited by this paper
• Human P-glycoprotein transports cyclosporin A and FK506.

  1993cited by this paper
• Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity.

  1992cited by this paper
• Role of endothelin in cyclosporine-induced glomerular dysfunction.

  1990cited by this paper
• Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat.

  1990cited by this paper

• Development of a Physiologically Based Pharmacokinetic Model to Evaluate Dosing Regimens of Cyclosporine as a Precipitant of Organic Anion Transporting Polypeptide 1B (OATP1B)‐ and CYP3A4‐Mediated Drug–Drug Interactions

  2025cites this paper
• The Effect of Drug–Drug Interactions on the Pharmacokinetics of Isavuconazole: A Comprehensive Review

  2025cites this paper
• Selection of Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension: A Comprehensive Narrative Review

  2025cites this paper
• Drug Interactions Associated With Therapies for Pulmonary Arterial Hypertension

  2022cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Progress in the Consideration of Possible Sex Differences in Drug Interaction Studies.

  2019cites this paper
• Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?

  2019cites this paper
• Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

  2018cites this paper
• Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

  2018cites this paper
• Identification of drug transporters involved in the uptake and efflux of rhein in hepatocytes

  2017cites this paper
• Brain and the Drug Transporters

  2017cites this paper
• The Discovery of Macitentan - A Standard Medicinal Chemistry Program?

  2017cites this paper
• Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU

  2016cites this paper
• Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU

  2016cites this paper
• The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 Genotype

  2015cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review

  2015cites this paper
• New pharmacotherapy options for pulmonary arterial hypertension

  2015cites this paper
• The impact of drug-drug interactions on pulmonary arterial hypertension therapy.

  2014cites this paper
• Presurgical Pulmonary Evaluation in Renal Transplant Patients

  2014cites this paper
• Macitentan Does Not Interfere with Hepatic Bile Salt Transport

  2014cites this paper
• Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

  2014cites this paper
• Drug Interactions in Organ Transplantation

  2014cites this paper
• Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information

  2014cites this paper
• Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU

  2014influential citation
• P-glycoprotein (P-gp/MDR1)/ABCB1

  2013cites this paper
• PHPN: Drug Interactions of Current Pulmonary Arterial Hypertension Therapies in Abdominal Organ Transplant Recipients

  2013cites this paper
• Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1

  2013cites this paper
• Anti-inflammatory and immunosuppressive agents in PAH.

  2013cites this paper
• Organic anion-transporting polypeptides (OATPs/SLCOs)

  2013cites this paper
• Targeted therapies: endothelin receptor antagonists

  2013cites this paper
• An update on the use of ambrisentan in pulmonary arterial hypertension

  2012cites this paper
• Safety and efficacy evaluation of ambrisentan in pulmonary hypertension

  2012cites this paper
• The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists.

  2012cites this paper
• Current and Future Tools for Predicting Clinical Drug–Drug Interactions

  2012cites this paper
• Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

  2012cites this paper
• Ambrisentan: a guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

  2011cites this paper
• Pharmaceutical Relevance of Drug Transporter Malfunctions

  2011cites this paper
• Ambrisentan

  2011cites this paper
• Current understanding of hepatic and intestinal OATP-mediated drug–drug interactions

  2011cites this paper
• Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

  2011cites this paper
• Organic anion transporting polypeptides (OATPs): regulation of expression and function.

  2011cites this paper